Renal oncocytoma: a comparative clinicopathologic study and fluorescent in-situ hybridization analysis of 73 cases with long-term follow-up
© Dvorakova et al; licensee BioMed Central Ltd. 2010
Received: 24 February 2010
Accepted: 24 May 2010
Published: 24 May 2010
Clinical studies have confirmed that renal oncocytoma (RO) is a benign neoplasm with excellent prognosis. In diagnostically challenging cases of renal oncocytic epithelial neoplasms, fluorescent in-situ hybridization (FISH) is increasingly being used and its ability to distinguish RO from chromophobe renal cell carcinoma (ChRCC) has been documented. In this study, we evaluated the differential diagnostic contribution of FISH in cases of RO.
Clinicopathologic data and glass slides from 73 patients with RO were reviewed; 20 cases of ChRCC were included for comparison. FISH analysis of formalin-fixed, paraffin-embedded sections was performed using centromeric probes for chromosomes 1, 2, 7 and 17. FISH analysis revealed ROs had frequent loss of signal for chromosome 1 (56%) and 17 (44%). Tumors with more than one loss were common (41%) and 10% cases showed loss of all chromosomes examined. A total of 18% cases did not show any abnormality.
Our study shows that chromosomal abnormalities in both ROs and ChRCCs are common with frequent loss of chromosomes 1 and 17. No association was found between overall patient survival and the extent of chromosomal abnormalities. FISH results, even those showing significant chromosomal abnormalities, should not alter the primarily morphology-based diagnosis of RO.
Renal oncocytomas (ROs) comprise approximately 3-7% of renal epithelial neoplasms [1–3]. Common origin of RO and chromophobe renal cell carcinoma (ChRCC) from the intercalated cells of collecting ducts explains the histomorphologic, immunophenotypical, ultrastructural and molecular similarities of both neoplasms [2–7]. The benign nature of ROs, compared with the potential of ChRCCs for metastases and sarcomatoid transformation [8, 9] has led to search for a confirmatory diagnostic modality; a broad array of ancillary studies have been employed in the differential diagnosis of the two neoplasms, including electron microscopy, flow cytometry, immunohistochemistry, cytogenetics and fluorescent in situ hybridization (FISH).
Cytogenetic studies of RO revealed genetic heterogeneity of these neoplasms; three distinct subsets were identified: 1) translocation between 11q13 and other chromosomes, 2) loss of 1/1p followed by loss of chromosome Y or 14 and 3) non-recurrent or no detectable aberrations . Molecular and fluorescent in-situ hybridization (FISH) studies of ROs described partial or total loss of chromosome 1 to be the most consistently reported clonal chromosomal abnormality in RO [11–13] with a possible tumor suppressor gene expected on chromosome 1p . In contrast, ChRCC was consistently found to display multiple losses of chromosomes 1, 2, 6, 10, 17 and 21 [12, 15–17]. FISH was considered to be a potentially useful tool for distinguishing RO from ChRCC, with the former showing no abnormality or loss of chromosome 1 and the latter usually multiple additional chromosomal aberrations [12, 18].
Based on the current data on genetic abnormalities occurring in ROs, we have employed an abbreviated FISH panel for chromosomes 1, 2, 7 and 17 in our institution that would aid in their differential diagnosis. In this study, we present our experience with this FISH panel and its contribution in the differential diagnosis along with survival data of 73 patients with RO.
Materials and methods
The pathology records of the University of Pittsburgh were reviewed to find all patients who underwent primary nephrectomy for renal oncocytoma in the period of 25 years (1981 - 2006). Seventy-three cases of renal oncocytoma were selected from the UPMC archives using conventional histologic examination by two pathologists. For each patient, the data from the final surgical pathology report as well as from the clinical records were retrieved. In addition, 20 cases of ChRCC (11 cases of classic and 9 cases of eosinophilic variant) were included for comparison. Since the previously published FISH results did not show significant difference in observed abnormalities between the classic and eosinophilic variant of ChRCC , the two subtypes were not distinguished further in our study. Five (5) non-neoplastic kidney tissue sections were evaluated as a negative control.
Fluorescent in-situ hybridization
Formalin-fixed paraffin-embedded sections were mounted and serially sectioned at 5-mm intervals. H&E section was used by the pathologist to determine the area of the tissue to be targeted for analysis. FISH slides were deparaffinized in xylene twice for 10 minutes, dehydrated twice with 100% ethanol and then pretreated using the Vysis Paraffin Pretreatment Kit. Slides were digested for 18 minutes in protease solution (0.5 mg/ml) at 37°C. FISH was performed using CEP1, CEP2, CEP7 and CEP17 centromere probes (Vysis, Inc., Downers Grove, IL). The target slide was denatured at 75°C for 5 minutes and dehydrated in 70%, 85%, 100% ethanol. Slides were incubated with probe overnight at 42°C in a humidified chamber. Post-hybridization washes were performed using 0.4× SSC/0.3% Igepal (Sigma) at 72°C for 2 minutes, followed by a room temperature 2 × SSC/0.1% Igepal wash for 30 seconds. Slides were air-dried in the dark and counterstained with DAPI (Vysis, Inc). Analysis was performed using a Nikon Optiphot-2 (Nikon, Inc) and Quips Genetic Workstation equipped with Chroma Technology 83000 filter set with single band excitors for Texas Red/Rhodamine, FITC, DAPI (UV 360 nm) (Vysis, Inc). Only individual and well delineated cells were scored, overlapping cells were excluded from the analysis. At least 60 cells were analyzed in the targeted region. Signal loss was considered significant if present in more than 30% of cells, gain if present in more than 20% of cells examined.
Clinico-pathological characteristics of the study population with clinical follow-up
In the RO group, the study population included 51 males and 22 females (male to female ratio 2.3:1) with an average age of 67 (range 29 - 83) years. A total of 32 patients 44%) underwent partial nephrectomy (nephron sparing surgery), the remaining 41 patients (56%) radical nephrectomy with or without ipsilateral adrenalectomy. The mean tumor size was 4.0 cm (range from 1 - 21 cm). Small vessel invasion was present in 4 (5.5%) cases, and invasion into perinephric adipose tissue in 5 (6.8%) cases. None of the patients had evidence of metastatic disease at diagnosis. After a mean follow-up of 64 months (range from 1 to 293 months), a total of 46 (63%) of patients were alive with no evidence of disease; 14 (19%) had died of other causes and no follow up was available for 13 (18%) patients. None of the patients had disease recurrence nor developed metastases. The control ChRCC group consisted of 11 males and 9 females male to female ratio 1.2:1) with a mean age of 64 (range 35 - 88) years (Table 1). Average tumor size was 6.1 cm (range 1 - 14.5 cm). A total of 8 patients (40%) were treated with partial nephrectomy, 12 (60%) with radical nephrectomy. Small vessel invasion was present in 3 (15%) cases, and invasion into perinephric adipose tissue in 2 (10%) cases; one patient had tumor grossly extending into the renal vein. After a mean follow up of 60 months (range from 25 - 87 months), one patient with a tumor extending into the perinephric adipose tissue developed local recurrence 25 months after a radical nephrectomy. Similarly to the renal oncocytoma group, none of the patients with available follow-up died of disease or developed metastases.
In 32 cases, the initial diagnosis of renal oncocytoma was based on histology alone (44%); a total of 41 (56%) cases had some ancillary studies, such as electron microscopy (2 cases, 3%), DNA ploidy analysis (3 cases, 4%), FISH (24 cases, 33%) or histochemistry for Hale's colloidal iron (12 cases, 16%). A total of 68 cases (93%) were initially diagnosed as oncocytoma; however, 5 cases (7%) were diagnosed using descriptive terms such as "atypical oncocytic neoplasm" or "renal cell carcinoma of oncocytic type (oncocytoma)". In contrast, all of the chromophobe renal cell carcinomas were initially worked-up using ancillary studies such as Hale's colloidal iron histochemical stain (19/20 cases, 95%) or FISH (12/20 cases, 60%).
ChRCCs consistently showed multiple chromosomal abnormalities, and 6/20 (30%) of cases were abnormal in all chromosomes examined (Table 2, Figure 3). The one case with a completely normal FISH analysis was a case of eosinophilic chromophobe renal cell carcinoma with a Fuhrman nuclear grade 2 and a strong cytoplasmic positivity for Hale's colloidal iron. None of our negative control sections from the adjacent non-neoplastic renal tissue showed any losses or gains exceeding the 30 and 20% threshold, respectively.
Renal oncocytomas are relatively uncommon neoplasms accounting for 3-7% of primary renal epithelial neoplasms [1–3]. The majority of RO has distinctive cytoarchitectural features that permit accurate diagnosis; however, the occasional differential diagnostic challenge between RO and ChRCC has been repeatedly acknowledged in the literature [2, 3, 18, 19]. Both renal oncocytoma and chromophobe renal cell carcinoma originate form the collecting duct intercalated cells and can therefore share similar histomorphologic, immunophenotypical and ultrastructural characteristics [2–5], as well as gene expression profiles [6, 7, 20]. Renal oncocytomas can contain foci of atypical cells and show vascular space invasion or extracapsular extension not adversely affecting the overall excellent prognosis of this neoplasm [2, 3]; the metastatic potential of RO remains controversial .
Although ChRCC was found to have low metastatic potential and its prognosis and long term survival is considered to be excellent , ChRCC was also found to have a potential to recur, metastasize and undergo sarcomatoid transformation [8, 9]. The difficulty to distinguish the two neoplasms has been demonstrated by the broad array of ancillary studies employed so far routinely in the differential diagnosis such as electron microscopy, DNA flow cytometry, immunohistochemistry, cytogenetics, and FISH. A small proportion of renal epithelial neoplasms with eosinophilic cytoplasm cannot be definitively classified based on histology alone .
Based on published cytogenetic studies, ROs are genetically heterogeneous tumors. Fűzesi et.al proposed subclassification into 3 groups: the first one defined by translocation between 11q13 and other chromosomes, the second with a loss of 1/1p followed by loss of chromosome Y or 14, and the third with non-recurrent or no detectable aberrations . Prior FISH studies have detected a varying incidence of partial or total loss of chromosome 1 in RO ranging from 10 - 59% [11–13], whereas loss of other autosomes was not detected. In contrast, ChRCCs were consistently found to have multiple recurrent chromosomal abnormalities, such as losses of chromosomes 1, 2, 6, 10, 13, 17 and 21 by FISH, conventional cytogenetics and comparative genomic hybridization [12, 15, 16, 18, 22]. No significant difference in chromosomal abnormalities was found between the classic and eosinophilic variant of ChRCC . Since both RO and ChRCC can show loss of chromosomes 1 and Y, it was hypothesized that a subset of ROs may progress to ChRCC with subsequent loss of chromosomes 2, 6, 10, 13, 17 and 21 .
Based on the above data, we have employed an abbreviated FISH panel for chromosomes 1, 2, 7 and 17 to guide us in the differential diagnosis of renal epithelial neoplasms with eosinophilic cytoplasm. Whereas an isolated loss of chromosome 1 would favor the diagnosis of RO, multiple losses of chromosomes 1, 2 and 17 were expected in ChRCC cases. Although abnormalities involving chromosome 7 are not specific and have been reported in other types of malignancies, we included this chromosome since its trisomy (together with trisomy 17) was observed in papillary renal cell carcinoma [24, 25] that can rarely contribute to the pool of unclassifiable cases of renal epithelial neoplasms with eosinophilic cytoplasm.
In our current study, the incidence of chromosomal abnormalities in ROs (60/73 cases, 82%) was significantly higher than in the previous reports [10, 12, 18]. Brunelli et al.  analyzed 10 RO by FISH using centromeric probes for chromosomes 1, 2, 6, 10 and 17; only one case showed loss of signal for chromosome 1, and no other aberrations were detected. The criteria for chromosomal losses were similar (22 - 30% of cells with one signal vs. 30% in the current study); however, the number of nuclei examined in our study was lower (60 vs. 100 - 200), but sufficient for overall assessment. Only one similar case of an incidentally discovered RO with multiple chromosomal losses involving chromosomes 1, 2, 3, 6, 8, 9, 15, 17, 21 and 22 in a 55-year-old male was identified in the literature . The second most common genetic alteration in our subset of RO was the loss of signal for chromosome 17 (32/73, 44%); a common finding reported in ChRCCs and also observed in the control ChRCC subset in our study. Recently, a tumor suppressor gene associated with Birt-Hogg-Dubé syndrome was mapped to the pericentromeric region of 17p chromosome [27–30]. Birt-Hogg-Dubé syndrome is a rare genodermatosis characterized by the development of dermatologic lesions (fibrofolliculomas, trichodiscomas, acrochordons), lung cysts with spontaneous pneumothorax, colonic polyps and also renal tumors, mainly hybrid oncocytic neoplasms with both ChRCC and RO morphology, ChRCCs, clear cell carcinomas, oncocytomas and papillary renal cell carcinomas .
A total of 3/73 RO cases showed loss of chromosome 1 and gain of chromosome 7 and/or 17; morphologically, 2 cases displayed characteristic alternating nested and organoid growth patterns; the third case had predominantly tubulocystic arrangement of typical oncocytes. All three were initially diagnosed as RO without any ancillary studies. Gains of chromosome 7 and/or 17 without any accompanying chromosomal loss was observed in 4/73 cases; histologic review confirmed the initial diagnosis of RO in all four cases; however, only some of the original histologic sections were available for review in 3 cases precluding a definitive diagnosis. RO cases with extracapsular or vascular space invasion usually showed multiple chromosomal losses or gains; however, one of the cases with perirenal soft tissue extension was normal by FISH. Long term follow-up of patients included in our study confirmed the excellent prognosis of RO as none of the patients died of disease, developed metastases or local recurrence. No association was found between overall patient survival and the extent of chromosomal abnormalities detected by FISH.
The incidence of chromosomal abnormalities in ChRCC was in agreement with previous studies [12, 15, 16]; 19/20 (95%) cases showed multiple losses involving chromosomes 1, 2 and 17 in different combinations; in addition, loss of chromosome 7 was observed in 6/20(30%) cases and 6/20 (30%) cases showed loss of signals for all chromosomes examined (Figure 2). A total of 3/20 (all classic ChRCCs positive for colloidal iron) had chromosomal losses associated with gains of chromosome 7 and/or 17. Only one case did not show any gains or losses; review of the slides revealed an eosinophilic variant of ChRCC with a strong cytoplasmic positivity for colloidal iron (Figure 3). Rare cases of ChRCCs with no chromosomal abnormality have been reported [12, 16]. One patient in the control ChRCC group developed local recurrence 25 months after partial nephrectomy; the reminder of the patients was disease free or died of other causes.
Our FISH study of ROs, which is largest to date, was based on a series of well-defined oncocytomas diagnosed according to the current morphologic WHO classification criteria . Our results show that chromosomal abnormalities in ROs are common and include frequent losses of chromosomes 1 and 17, yet another feature that overlaps with ChRCCs. FISH was not found to be a useful diagnostic modality in the differential diagnosis of RO and ChRCC and did not alter the initial primarily morphology-based diagnosis of renal oncocytoma in any of the 73 cases. Our results suggest that RO and ChRCC are genetically related tumors and support the hypothesis that they might rather represent a spectrum of neoplasia than two distinct neoplasms. This finding is further supported by the concurrent RO and ChRCC as well as their hybrid form in patients with Birt-Hogg-Dubé syndrome. The significance of specific combinations of chromosomal abnormalities as well as the impact on prognosis, propensity to metastasize, recur and undergo sarcomatoid transformation remains to be further investigated.
The authors acknowledge the funding for this work was received from the Department of Pathology, University of Pittsburgh.
- Reuter VE, Davis CJ, Moch H: Oncocytoma. Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs. World Health Classification of Tumours. 2004, Lyon, France: IARC Press, 6: 9-87.
- Amin MB, Crotty TB, Tickoo SK, Farrow GM: Renal oncocytoma: a reappraisal of morphologic features with clinicopathologic findings in 80 cases. [see comment][erratum appears in Am J Surg Pathol 1997 Jun;21(6):742]. Am J Surg Pathol. 1997, 21 (1): 1-12. 10.1097/00000478-199701000-00001.View ArticlePubMed
- Perez-Ordonez B, Hamed G, Campbell S: Renal oncocytoma: a clinicopathologic study of 70 cases. Am J Surg Pathol. 1997, 21 (8): 871-83. 10.1097/00000478-199708000-00001.View ArticlePubMed
- Tickoo SK, Amin MB: Discriminant nuclear features of renal oncocytoma and chromophobe renal cell carcinoma. Analysis of their potential utility in the differential diagnosis. Am J Clin Pathol. 1998, 110 (6): 782-7.PubMed
- Tickoo SK, Lee MW, Eble JN: Ultrastructural observations on mitochondria and microvesicles in renal oncocytoma, chromophobe renal cell carcinoma, and eosinophilic variant of conventional (clear cell) renal cell carcinoma. Am J Surg Pathol. 2000, 24 (9): 1247-56. 10.1097/00000478-200009000-00008.View ArticlePubMed
- Young AN, Amin MB, Moreno CS: Expression profiling of renal epithelial neoplasms: a method for tumor classification and discovery of diagnostic molecular markers. [erratum appears in Am J Pathol 2002 Jun;160(6):2311]. Am J Pathol. 2001, 158 (5): 1639-51.PubMed CentralView ArticlePubMed
- Schuetz AN, Yin-Goen Q, Amin MB: Molecular classification of renal tumors by gene expression profiling. J Mol Diagn. 2005, 7 (2): 206-18.PubMed CentralView ArticlePubMed
- Akhtar M, Tulbah A, Kardar AH, Ali MA: Sarcomatoid renal cell carcinoma: the chromophobe connection. Am J Surg Pathol. 1997, 21 (10): 1188-95. 10.1097/00000478-199710000-00009.View ArticlePubMed
- de Peralta-Venturina M, Moch H, Amin M: Sarcomatoid differentiation in renal cell carcinoma: a study of 101 cases. Am J Surg Pathol. 2001, 25 (3): 275-84. 10.1097/00000478-200103000-00001.View ArticlePubMed
- Fuzesi L, Frank D, Nguyen C, Ringert RH, Bartels H, Gunawan B: Losses of 1p and chromosome 14 in renal oncocytomas. Cancer Genet Cytogenet. 2005, 160 (2): 120-5. 10.1016/j.cancergencyto.2004.12.010.View ArticlePubMed
- Brown JA, Takahashi S, Alcaraz A: Fluorescence in situ hybridization analysis of renal oncocytoma reveals frequent loss of chromosomes Y and 1. [see comment]. J Urol. 1996, 156 (1): 31-5. 10.1016/S0022-5347(01)65929-9.View ArticlePubMed
- Brunelli M, Eble JN, Zhang S, Martignoni G, Delahunt B, Cheng L: Eosinophilic and classic chromophobe renal cell carcinomas have similar frequent losses of multiple chromosomes from among chromosomes 1, 2, 6, 10, and 17, and this pattern of genetic abnormality is not present in renal oncocytoma. Mod Pathol. 2005, 18 (2): 161-9. 10.1038/modpathol.3800286.View ArticlePubMed
- Paner GP, Lindgren V, Jacobson K: High incidence of chromosome 1 abnormalities in a series of 27 renal oncocytomas: cytogenetic and fluorescence in situ hybridization studies. Arch Pathol Lab Med. 2007, 131 (1): 81-5.PubMed
- Thrash-Bingham CA, Salazar H, Greenberg RE, Tartof KD: Loss of heterozygosity studies indicate that chromosome arm 1p harbors a tumor supressor gene for renal oncocytomas. Genes Chromosomes Cancer. 1996, 16 (1): 64-7. 10.1002/(SICI)1098-2264(199605)16:1<64::AID-GCC9>3.0.CO;2-1.View ArticlePubMed
- Iqbal MA, Akhtar M, Ulmer C, Al-Dayel F, Paterson MC: FISH analysis in chromophobe renal-cell carcinoma. Diagn Cytopathol. 2000, 22 (1): 3-6. 10.1002/(SICI)1097-0339(200001)22:1<3::AID-DC2>3.0.CO;2-0.View ArticlePubMed
- Speicher MR, Schoell B, du Manoir S: Specific loss of chromosomes 1, 2, 6, 10, 13, 17, and 21 in chromophobe renal cell carcinomas revealed by comparative genomic hybridization. Am J Pathol. 1994, 145 (2): 356-64.PubMed CentralPubMed
- Berg van den E, Hout van der AH, Oosterhuis JW: Cytogenetic analysis of epithelial renal-cell tumors: relationship with a new histopathological classification. Int J Cancer. 1993, 55 (2): 223-7. 10.1002/ijc.2910550210.View ArticlePubMed
- Herbers J, Schullerus D, Chudek J: Lack of genetic changes at specific genomic sites separates renal oncocytomas from renal cell carcinomas. J Pathol. 1998, 184 (1): 58-62. 10.1002/(SICI)1096-9896(199801)184:1<58::AID-PATH987>3.0.CO;2-1.View ArticlePubMed
- Abrahams NA, MacLennan GT, Khoury JD: Chromophobe renal cell carcinoma: a comparative study of histological, immunohistochemical and ultrastructural features using high throughput tissue microarray. Histopathology. 2004, 45 (6): 593-602. 10.1111/j.1365-2559.2004.02003.x.View ArticlePubMed
- Chen YT, Tu JJ, Kao J, Zhou XK, Mazumdar M: Messenger RNA expression ratios among four genes predict subtypes of renal cell carcinoma and distinguish oncocytoma from carcinoma. Clin Cancer Res. 2005, 11 (18): 6558-66. 10.1158/1078-0432.CCR-05-0647.View ArticlePubMed
- Kwast Van der T, Perez-Ordonez B: Renal oncocytoma, yet another tumour that does not fit in the dualistic benign/malignant paradigm? [comment]. J Clin Pathol. 2007, 60 (6): 585-6. 10.1136/jcp.2006.044438.PubMed CentralView ArticlePubMed
- Amin MB, Amin MB, Tamboli P: Prognostic impact of histologic subtyping of adult renal epithelial neoplasms: an experience of 405 cases. [see comment]. Am J Surg Pathol. 2002, 26 (3): 281-91. 10.1097/00000478-200203000-00001. Verdorfer I, Hobisch A, Hittmair A, et al.: Cytogenetic characterization of 22 human renal cell tumors in relation to a histopathological classification. Cancer Genet Cytogenet 1999, 111(1): 61-70.View ArticlePubMed
- Dijkhuizen T, Berg van den E, Storkel S: Renal oncocytoma with t(5;12;11), der(1)1;8) and add(19): "true" oncocytoma or chromophobe adenoma?. Int J Cancer. 1997, 73 (4): 521-4. 10.1002/(SICI)1097-0215(19971114)73:4<521::AID-IJC11>3.0.CO;2-C.View ArticlePubMed
- Corless CL, Aburatani H, Fletcher JA, Housman DE, Amin MB, Weinberg DS: Papillary renal cell carcinoma: quantitation of chromosomes 7 and 17 by FISH, analysis of chromosome 3p for LOH, and DNA ploidy. Diagn Mol Pathol. 1996, 5 (1): 53-64. 10.1097/00019606-199603000-00009.View ArticlePubMed
- Brunelli M, Eble JN, Zhang S, Martignoni G, Cheng L: Gains of chromosomes 7, 17, 12, 16, and 20 and loss of Y occur early in the evolution of papillary renal cell neoplasia: a fluorescent in situ hybridization study. Mod Pathol. 2003, 16 (10): 1053-9. 10.1097/01.MP.0000090924.90762.94.View ArticlePubMed
- Gregori-Romero MA, Morell-Quadreny L, Llombart-Bosch A: A singular case of near-haploid stemline karyotype in a renal oncocytoma. Cancer Genet Cytogenet. 1996, 92 (1): 28-30. 10.1016/S0165-4608(96)00026-X.View ArticlePubMed
- Schmidt LS, Warren MB, Nickerson ML: Birt-Hogg-Dube syndrome, a genodermatosis associated with spontaneous pneumothorax and kidney neoplasia, maps to chromosome 17p11.2. Am J Hum Genet. 2001, 69 (4): 876-82. 10.1086/323744.PubMed CentralView ArticlePubMed
- Nickerson ML, Warren MB, Toro JR: Mutations in a novel gene lead to kidney tumors, lung wall defects, and benign tumors of the hair follicle in patients with the Birt-Hogg-Dube syndrome. Cancer Cell. 2002, 2 (2): 157-64. 10.1016/S1535-6108(02)00104-6.View ArticlePubMed
- Linehan WM, Walther MM, Zbar B: The genetic basis of cancer of the kidney. J Urol. 2003, 170 (6 Pt 1): 2163-72. 10.1097/01.ju.0000096060.92397.ed.View ArticlePubMed
- da Silva NF, Gentle D, Hesson LB, Morton DG, Latif F, Maher ER: Analysis of the Birt-Hogg-Dube (BHD) tumour suppressor gene in sporadic renal cell carcinoma and colorectal cancer. J Med Genet. 2003, 40 (11): 820-4. 10.1136/jmg.40.11.820.View ArticlePubMed
- Pavlovich CP, Walther MM, Eyler RA: Renal tumors in the Birt-Hogg-Dube syndrome. Am J Surg Pathol. 2002, 26 (12): 1542-52. 10.1097/00000478-200212000-00002.View ArticlePubMed
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.